Insmed CFO Sara Bonstein to step down October 30, 2026

Insmed Incorporated announced on October 5, 2026 that Chief Financial Officer Sara Bonstein will depart the company effective October 30, 2026. The company disclosed the CFO's separation in an 8-K filing and said a search is underway to find her replacement.¹

Bonstein will remain CFO through the company's third-quarter 2026 earnings report and is set to join the earnings call on October 29, 2026.¹ Insmed stated that her departure is unrelated to any disagreement over accounting practices, financial statements, internal controls, or operations.¹ Under her amended employment agreement dated April 1, 2022, Bonstein will receive benefits specified in Section 6.e of that agreement.¹

CEO Will Lewis credited Bonstein's tenure, noting Insmed raised more than $4.2 billion in capital during her time as CFO¹, and said the company now expects to reach cash flow positivity next year with a path toward sustained top-line growth and bottom-line profitability, according to Lewis.¹

Alongside the leadership announcement, Insmed reaffirmed full-year 2026 revenue guidance of $1.25 billion to $1.40 billion for BRINSUPRI (brensocatib) and $450 million to $470 million for ARIKAYCE (amikacin liposome inhalation suspension).¹

The company also confirmed its third-quarter 2026 earnings timeline. Insmed will release third-quarter 2026 results on October 29, 2026, with a conference call for investors beginning at 8:00 a.m. ET that day to discuss results and provide a business update.¹